Your Article Summary
See Latest ArticlesOlanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues
Neuropsychiatric Disease and Treatment, 07/02/09
Bobo WV et al. - While effective during acute-phase treatment, questions remain regarding the long-term efficacy and safety of FLX/OLZ relative to antidepressant monotherapy and other combination strategies. Efforts aimed at determining the placement of FLX/OLZ among the available options for addressing TRD are limited by lack of comparison and sequential treatment studies. Important aspects of study design and directions for future research are discussed.
Methods- In each study, the FLX/OLZ combination caused rapid reduction in Montgomery-Asberg Depression Rating scale scores, with two of the four studies showing significantly greater improvement than antidepressant monotherapy at study endpoint.
- Effects of the FLX/OLZ combination were strongest in cases where failure to respond to two antidepressants prior to randomization was established during the current depressive episode.
- The FLX/OLZ combination was well-tolerated; however, body weight gain and increases in prolactin were greater than that of the antidepressant monotherapy groups, and were comparable to that of OLZ monotherapy.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
When Opioids Have Been Prescribed for Chronic Pain
Journal Of Pain & Palliative Care Pharmacotherapy, 12/02/09
Impaired Renal Function and Opioid Toxicity
Journal Of Pain & Palliative Care Pharmacotherapy, 12/02/09
Expand the Pharyngitis Paradigm for Adolescents and Young Adults
Annals of Internal Medicine, 12/02/09
Today in Psychiatry...keeping you current
Receive free subspecialty "5-minute updates" via email
Screening for Depression in Adults: U.S. Preventive Services Task Force Recommendation Statement
Annals of Internal Medicine, 12/02/09
Increased Cold-Pain Thresholds in Major Depression
The Journal of Pain, 12/02/09
Olanzapine for the Treatment of Acquired Neurogenic Stuttering
Journal of Psychiatric Practice, 12/02/09